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The exact nature of the comorbidity between cardiovascular disease (CVD) and major depressive disorder (MDD) is poorly
understood. The proposed mechanisms include various biochemical and molecular pathways as well as health behaviors such
as physical inactivity. One possible link between MDD and CVD is increased platelet activity and blood viscosity. Recently, it
was discovered that platelets express functional subtype of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)
receptors, for example, glutamate receptor 1 (GluR1). Here, I propose that this type of AMPA receptor could play a role in
comorbidMDDandCVD,andantidepressantsmayinterferewithplateletactivationviadirectorindirecteﬀectsonplateletGluR1
phosphorylation. Testing this hypothesis could provide a novel view on the pathobiological mechanisms of comorbid MDD and
CVD. With respect to the recently discovered role of AMPA receptors in regulating platelet activation and thrombosis, it appears
that the information about the putative eﬀects of psychoactive AMPA-modifying drugs on platelet AMPA receptors would be
critical in evaluating the putative eﬀects of such drugs on CVD.
Copyright © 2009 Hu Chen. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Epidemiological studies have identiﬁed a high incidence
of comorbidity between cardiovascular disease (CVD) and
major depressive disorder (MDD). These studies note that
patients with MDD are at greater risk of developing CVD
[1]. Further, they prompted the American Heart Association
to recommend routine screening for depression in patients
with coronary heart disease, a recommendation that still
needs to be fully implemented [2]. The exact nature of the
MDD-CVD association is poorly understood. The proposed
mechanisms of this link include various biological, that is,
biochemical and molecular pathways as well as the hypoth-
esis that the association between depressive symptoms and
cardiovascular events could be driven by health behaviors,
especially physical inactivity [3].
One prominently hypothesized link between MDD and
CVD includes increased platelet activity and blood viscosity
in these patients [4–7]. It has been suggested that serotonin
and its molecular/cellular targets are altered in patients with
MDD in a way that leads to increased platelet activation
and enhanced risk for CVD [4]. Several studies have shown
that this abnormal activation of platelets can be attenuated
by psychotherapy and by treatment with selective serotonin
reuptake inhibitors (SSRIs) [8–10].
Recently, it was discovered that platelets express the
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) receptors for the excitatory neurotransmitter
glutamate [11]. Furthermore, these authors showed that
an AMPA receptor subtype, glutamate receptor 1 (GluR1),
mediates the action of glutamate as a regulator of platelet
activation, and they suggested that the GluR1 receptor is a
novel antithrombotic target. Here, I propose that this type of
glutamate receptor could play a role in comorbid MDD and
CVD.
2. Presentationof the Hypothesis
Ionotropicglutamatereceptorsareligand-gatedionchannels
that can be subdivided into three classes: NMDA (N-
methyl-d-aspartate), kainate, and AMPA receptors. GluR1,2 Cardiovascular Psychiatry and Neurology
one of AMPA receptor subunits, mediates transmission
and plasticity at excitatory synapses in a manner which is
positively regulated by phosphorylation at Ser845-GluR1,
a protein kinase A (PKA) site, and at Ser831-GluR1, a
calcium/calmodulin-dependent kinase II (CaMKII) or pro-
tein kinase C (PKC) site [12, 13].
Recent work by Morrell et al. [11] demonstrated
that activated platelets release glutamate and express
GluR1 AMPA subunits; glutamate increases agonist-induced
platelet activation. Furthermore, glutamate binding to the
AMPA receptors depolarized platelets (an important step in
platelet activation), and platelets treated with an AMPAR
antagonist or platelets derived from GluR1 knockout mice
were resistant to the eﬀects of AMPA. In addition, mice lack-
ing GluR1 have a prolonged time to thrombosis in vivo [11].
Thus, activation of GluR1 plays a role in accelerating throm-
bus formation and may contribute to development of CVD.
It has been noted that plasma concentrations of glu-
tamate are altered in MDD. Plasma levels of glutamate
increased with the severity of depression [14], and antide-
pressant therapy was capable of reducing these levels [15].
On the other hand, measurements of the platelet response
to glutamate revealed that platelet glutamate receptors are
supersensitive in MDD [16].
Considering the crucial role of increased GluR1 phos-
phorylation in the process of membrane insertion of these
subunits and in the consequent increased activity of these
AMPA receptors [17], and also considering known alter-
ations of protein kinase systems (including PKA) in mood
disorders [18], I hypothesize that altered platelet GluR1
phosphorylationinMDDmaycontributetocomorbidMDD
and CVD.
3. Antidepressantsand GluR1 Phosphorylation
The traﬃcking of the GluR1 from intracellular pools to cell
membranes is guided by a well-regulated pattern of receptor
phosphorylation. It has been suggested that phosphorylation
of GluR1 is involved in antidepressant-like actions [19].
However, the data on medication-induced alterations of
GluR1 phosphorylation are complex. Both an increase and
ad e c r e a s eo fG l u R 1p h o s p h o r y l a t i o nw e r eo b s e r v e di n
response to antidepressant treatment, and various antide-
pressants inﬂuence the phosphorylation of diﬀerent sites
of GluR1. For example, Svenningsson et al. [20]r e p o r t e d
that treatment with ﬂuoxetine increases phosphorylation at
the Ser845 but not the Ser831 site. In addition, another
antidepressant, tianeptine, which enhances the reuptake of
serotonin instead of inhibiting it, increased Ser831 phos-
phorylation in the frontal cortex and CA3 region of the
hippocampus but increased Ser845 phosphorylation only
in the CA3 region. Behavioral analyses showed that mice
bearing point mutations at both Ser831 and Ser845 when
treated with saline exhibit increased immobility in the tail
suspension test (i.e., depression-like behavior) compared to
their wild-type counterparts. Chronic tianeptine treatment
reduced this immobility in wild-type mice but not in phos-
phomutant GluR1 mice [21]. Recent ﬁndings in animal and
human studies suggest that minocycline has antidepressant-
like neuroprotective eﬀects, and it has been shown to act
as an antidepressant in a rat model of depression [22]. In
vitro and in vivo studies showed that minocycline induces
GluR1 phosphorylation at both Ser845 and Ser831, and it
increases the surface content of GluR1 [23]. In contrast,
a subanesthetic dose of ketamine, which causes acute and
sustained antidepressant-like eﬀects, signiﬁcantly lowered
the levels of phosphorylated GluR1 at Ser845 [24].
4.PlateletActivationandAntidepressants
Antidepressants, particularly SSRIs, have been associated
with abnormal bleeding. Drugs with the highest degree
of serotonin reuptake inhibition, for example, ﬂuoxetine,
paroxetine, and sertraline, are more frequently associated
with abnormal bleeding and modiﬁcations of hemostasis
markers [25]. Thus, it has been inferred that SSRIs may
also bestow protection from myocardial infarction, even
compared to other classes of antidepressants. This has been
demonstrated in some clinical studies [26]. More recent
studies suggest that SSRIs exert a complex sequence of eﬀects
relevant to platelet activation and that, in some instances,
they may even be prothrombotic [27]. Since the known
antidepressants, in addition to their main eﬀects (e.g., sero-
tonin reuptake inhibition), also aﬀect multiple molecular
pathways (e.g., GluR1 signaling and phosphorylation), I
hypothesize that these drugs may interfere with platelet
activation via direct or indirect eﬀects on platelet GluR1
phosphorylation.
5.Testing the Hypothesis
The hypothesis that altered platelet GluR1 phosphorylation
inMDDmaycontributetocomorbidMDD,andCVDwould
be best tested in a clinical setting. Since several studies
have already established alterations of glutamate levels and
receptor activation in MDD patients versus controls, this
approach could be used to assess the phosphorylation of
platelet GluR1. Moreover, future clinical studies could focus
on patients with comorbid MDD and CVD. In addition, in
vitro studies with human platelets are warranted to verify
whether alterations of platelet GluR1 phosphorylation (e.g.,
induced by kinase inhibitors and activators) inﬂuence the
extent of GluR1 insertion into the platelet membrane and
whether they inﬂuence platelet activation.
The hypothesis that drugs used for treatment of MDD
may interfere with platelet activation could be tested both in
animal models and in a clinical setting. It would be useful
to compare the eﬀects of SSRIs with novel antidepressants
developed speciﬁcally to target AMPA receptors. These
studieswouldbeprimarilyexploratorybecausethepredicted
mechanisms of action of these drugs on GluR1 receptors
couldsigniﬁcantlydiﬀerinthecentralnervoussystem(CNS)
and in blood cells such as platelets.
With respect to the recently discovered role of AMPA
receptors in regulating platelet activation and possibly
playing a signiﬁcant role in thrombosis, it appears thatCardiovascular Psychiatry and Neurology 3
the information about the putative eﬀects of CNS AMPA-
acting drugs on platelet AMPA receptors would be critical
in evaluating the putative eﬀects of such drugs on CVD.
More generally, testing the here-proposed hypothesis could
provide a novel view on the pathobiological mechanisms of
comorbid MDD and CVD.
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